INM — InMed Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for InMed Pharmaceuticals, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | R2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -18.6 | -7.95 | -7.68 | -8.16 | -12.6 |
| Depreciation | |||||
| Non-Cash Items | 5.9 | 1.03 | 0.839 | 0.334 | 3.79 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.07 | -0.566 | -0.369 | -0.484 | -0.076 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -15.6 | -7.28 | -6.99 | -8.1 | -8.64 |
| Capital Expenditures | -0.039 | -0.16 | -0.009 | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.634 | -0.502 | 0 | 0 | 0 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.673 | -0.662 | -0.009 | 0 | 0 |
| Financing Cash Flow Items | -1.78 | -1.32 | — | -0.884 | -0.137 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 15.1 | 10.7 | 4.65 | 12.3 | 0.095 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.19 | 2.74 | -2.34 | 4.17 | -8.55 |